<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591744</url>
  </required_header>
  <id_info>
    <org_study_id>18162</org_study_id>
    <secondary_id>NCI-2018-01405</secondary_id>
    <secondary_id>18162</secondary_id>
    <nct_id>NCT03591744</nct_id>
  </id_info>
  <brief_title>Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia</brief_title>
  <official_title>Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies side effects of daratumumab, bortezomib, dexamethasone, pegylated&#xD;
      liposomal doxorubicin hydrochloride, and lenalidomide in treating participants with plasma&#xD;
      cell leukemia. Monoclonal antibodies, such as daratumumab, may interfere with the ability of&#xD;
      cancer cells to grow and spread. Bortezomib may stop the growth of cancer cells by blocking&#xD;
      some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as,&#xD;
      dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Giving daratumumab, bortezomib,&#xD;
      dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide in treating&#xD;
      participants with plasma cell leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose(s) (MTD)/recommended phase 2 dose(s) (RP2D) of,&#xD;
      bortezomib and pegylated liposomal doxorubicin hydrochloride (doxil) when given in&#xD;
      combination with fixed dose daratumumab, lenalidomide, and dexamethasone.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the tolerability and safety of the planned regimen, by evaluation of toxicities&#xD;
      including: type, frequency, severity, attribution, time course and duration.&#xD;
&#xD;
      II. To estimate and assess overall response rate, response duration, and survival&#xD;
      probabilities (overall and progression-free).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Quantify CD38+ cells from the peripheral blood mononuclear cells (PBMC) fraction,&#xD;
      including T, natural killer (NK), and monocytic subsets.&#xD;
&#xD;
      II. Assess possible changes in CD38 expression, as well as the co-receptor marker CD31,&#xD;
      overall and by response status (responder/non-responder).&#xD;
&#xD;
      III. Assess cytokine levels in peripheral blood plasma. IV. Quantify CD38+ cells from the&#xD;
      bone marrow CD-138 negative fractions and acellular fractions, including T, NK, and monocytic&#xD;
      subsets.&#xD;
&#xD;
      V. Assess possible changes in CD38 expression, as well as the co-receptor marker CD31,&#xD;
      overall and by response status (responder/non-responder).&#xD;
&#xD;
      VI. Assess cytokine levels in the bone marrow acellular fraction. VII. Investigate CD38&#xD;
      cellular localization in plasma cells and extracellular vesicles from blood plasma.&#xD;
&#xD;
      VIII. Assess messenger ribonucleic acid (mRNA) expression in the peripheral blood mononuclear&#xD;
      cell (PBMC), the bone marrow CD138-negative fraction, the T cell fraction, and plasma cells.&#xD;
&#xD;
      IX. Investigate epigenetic changes in CD38 mRNA expression.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive daratumumab intravenously (IV) on days 1, 8, 15, and 22, dexamethasone&#xD;
      IV/orally (PO) on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin&#xD;
      hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib subcutaneously&#xD;
      (SC) on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on&#xD;
      days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated&#xD;
      liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and&#xD;
      bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up&#xD;
      to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may&#xD;
      receive up to 8 courses at the discretion of treating physician.&#xD;
&#xD;
      After completion of study treatment, participants are followed up at 30 days and then every 3&#xD;
      months for 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Budgetary constraints&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 25, 2018</start_date>
  <completion_date type="Anticipated">October 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Observed toxicities will be tabulated using frequencies and percentages based on the CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate described by the International Myeloma Working Group (IMWG)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Response rates will also be evaluated based on number and type of prior therapy(ies); the exact binomial confidence interval (CI) will be calculated for these estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The overall response rate (ORR) will be estimated by the number of participants who achieve a confirmed response (stringent complete response [sCR]/complete response [CR]/very good partial response [VGPR] or partial response [PR]) divided by the total number of response evaluable participants. Response rates will also be evaluated based on number and type of prior therapy(ies); the exact binomial CI will be calculated for these estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>From date of first dose of study drug to date of death from any cause, assessed up to 18 months</time_frame>
    <description>Will be estimated using the product-limit method of Kaplan and Meier; 95% confidence intervals will be calculated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>From date of first dose of study drug to date of first documented disease relapse, progression or death from any cause, whichever occurs first, up to 18 months</time_frame>
    <description>Will be estimated using the product-limit method of Kaplan and Meier; 95% confidence intervals will be calculated using Greenwood's formula.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Plasma Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (daratumumab, bortezomib, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (daratumumab, bortezomib, chemotherapy)</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (daratumumab, bortezomib, chemotherapy)</arm_group_label>
    <other_name>Anti-CD38 Monoclonal Antibody</other_name>
    <other_name>Darzalex</other_name>
    <other_name>HuMax-CD38</other_name>
    <other_name>JNJ-54767414</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (daratumumab, bortezomib, chemotherapy)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (daratumumab, bortezomib, chemotherapy)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (daratumumab, bortezomib, chemotherapy)</arm_group_label>
    <other_name>ATI-0918</other_name>
    <other_name>Caelyx</other_name>
    <other_name>DOX-SL</other_name>
    <other_name>Doxil</other_name>
    <other_name>Doxilen</other_name>
    <other_name>Doxorubicin HCl Liposome</other_name>
    <other_name>doxorubicin hydrochloride liposome</other_name>
    <other_name>Duomeisu</other_name>
    <other_name>Evacet</other_name>
    <other_name>LipoDox</other_name>
    <other_name>Liposomal Adriamycin</other_name>
    <other_name>liposomal doxorubicin hydrochloride</other_name>
    <other_name>Liposomal-Encapsulated Doxorubicin</other_name>
    <other_name>Pegylated Doxorubicin HCl Liposome</other_name>
    <other_name>S-Liposomal Doxorubicin</other_name>
    <other_name>Stealth Liposomal Doxorubicin</other_name>
    <other_name>TLC D-99</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented informed consent of the participant and/or legally authorized&#xD;
             representative. Assent, when appropriate, will be obtained per institutional&#xD;
             guidelines.&#xD;
&#xD;
          -  Willingness to provide bone marrow and peripheral blood samples for research purposes.&#xD;
             If unavailable, exceptions may be granted with study principal investigator (PI)&#xD;
             approval.&#xD;
&#xD;
          -  All study participants must be registered into the mandatory Revlimid Risk Evaluation&#xD;
             and Mitigation Strategies (REMS) program and be willing to comply with its&#xD;
             requirements.&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt; 60.&#xD;
&#xD;
          -  Plasma cell leukemia; either newly diagnosed or relapsed: defined as the presence of &gt;&#xD;
             2 x 10^9/L peripheral blood plasma cells or plasmacytosis accounting for &gt; 20% of the&#xD;
             differential white cell count.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Absolute&#xD;
             neutrophil count (ANC) &gt;= 500/mm^3&#xD;
&#xD;
               -  NOTE: Growth factor is not permitted within 14 days of ANC assessment unless&#xD;
                  cytopenia is secondary ot disease involvement.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Total&#xD;
             bilirubin =&lt; 2.0 x ULN (unless has Gilbert's disease).&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Aspartate&#xD;
             aminotransferase (AST) =&lt; 3.0 x ULN.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Alanine&#xD;
             aminotransferase (ALT) =&lt; 3.0 x ULN.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Creatinine&#xD;
             clearance of &gt;= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Left&#xD;
             ventricular ejection fraction (LVEF) &gt; 45%&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Hemoglobin&#xD;
             &gt;= 8.0 g/dL&#xD;
&#xD;
               -  Note: Transfusion support is allowed.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated:&#xD;
             Seronegative for human immunodeficiency virus (HIV) antigen-antibody (Ag/Ab) combo,&#xD;
             hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative),&#xD;
             and syphilis (RPR).&#xD;
&#xD;
               -  If positive, hepatitis C RNA quantitation must be performed.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Meets other&#xD;
             institutional and federal requirements for infectious disease titer requirements.&#xD;
&#xD;
               -  Note: Infectious disease testing to be performed within 28 days prior to day 1 of&#xD;
                  protocol therapy.&#xD;
&#xD;
          -  Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Women of&#xD;
             childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine&#xD;
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be&#xD;
             required.&#xD;
&#xD;
          -  Agreement by females and males of childbearing potential* to use an effective method&#xD;
             of birth control or abstain from heterosexual activity for the course of the study&#xD;
             through at least 6 months after the last dose of protocol therapy.&#xD;
&#xD;
               -  Childbearing potential defined as not being surgically sterilized (men and women)&#xD;
                  or have not been free from menses for &gt; 1 year (women only).&#xD;
&#xD;
          -  Women of childbearing potential must follow pregnancy testing requirements as outline&#xD;
             in REMS program material.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progression or intolerance to daratumumab, bortezomib, or lenalidomide.&#xD;
&#xD;
          -  Prior stem cell transplant.&#xD;
&#xD;
          -  Participant is receiving concurrent chemotherapy or biologic or hormonal therapy for&#xD;
             cancer treatment.&#xD;
&#xD;
               -  Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin&#xD;
                  for diabetes) is acceptable.&#xD;
&#xD;
          -  Vaccination with live attenuated vaccines within 4 weeks of first study agent&#xD;
             administration.&#xD;
&#xD;
          -  Participant is currently using or has used immunosuppressive medication within 14 days&#xD;
             prior to the first study dose of study treatment. The following are exceptions:&#xD;
&#xD;
               -  Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular&#xD;
                  injection)&#xD;
&#xD;
               -  Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or equivalent&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., infusion-related&#xD;
                  reactions, computed tomography [CT] scan premedication).&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to study agent.&#xD;
&#xD;
          -  Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1&#xD;
             second (FEV1) &lt; 50% of predicted normal.&#xD;
&#xD;
          -  Has known moderate or severe persistent asthma within the past 2 years, or currently&#xD;
             has uncontrolled asthma of any classification.&#xD;
&#xD;
          -  Clinically significant uncontrolled illness.&#xD;
&#xD;
          -  Active infection requiring intravenous antibiotics or antifungals within 14 days prior&#xD;
             to start of study treatment.&#xD;
&#xD;
          -  Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Grade &gt;= 3 peripheral neuropathy, or grade &gt;= 2 with pain on clinical examination&#xD;
             during the screening period.&#xD;
&#xD;
          -  Evidence of current uncontrolled cardiovascular conditions, including cardiac&#xD;
             arrhythmias, congestive heart failure, angina, or myocardial infarction within the&#xD;
             past 6 months. Note: Prior to study entry, any electrocardiogram (ECG) abnormality at&#xD;
             screening must be documented by the investigator as not medically relevant.&#xD;
&#xD;
          -  Other active malignancy. Exceptions: Non-melanoma skin cancer, ductal breast carcinoma&#xD;
             in situ (DCIS) or carcinoma-in-situ of the cervix. Note: If there is a history or&#xD;
             prior malignancy, they must not be receiving other specific treatment for their&#xD;
             cancer. Prior malignancy treated with curative intent is not an exclusion.&#xD;
&#xD;
          -  Females only: Pregnant or breastfeeding.&#xD;
&#xD;
          -  Any other condition that would, in the Investigator's judgment, contraindicate the&#xD;
             patient's participation in the clinical study due to safety concerns with clinical&#xD;
             study procedures.&#xD;
&#xD;
          -  Prospective participants who, in the opinion of the investigator, may not be able to&#xD;
             comply with all study procedures (including compliance issues related to&#xD;
             feasibility/logistics).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Krishnan</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

